Nuveen Asset Management LLC Has $235,000 Stock Position in 908 Devices Inc. (NASDAQ:MASS)

Nuveen Asset Management LLC decreased its holdings in shares of 908 Devices Inc. (NASDAQ:MASS) by 47.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 106,951 shares of the company’s stock after selling 97,420 shares during the quarter. Nuveen Asset Management LLC’s holdings in 908 Devices were worth $235,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Hsbc Holdings PLC increased its stake in shares of 908 Devices by 32.2% during the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company’s stock worth $46,000 after purchasing an additional 5,112 shares during the last quarter. LPL Financial LLC grew its stake in 908 Devices by 13.0% in the 4th quarter. LPL Financial LLC now owns 63,287 shares of the company’s stock valued at $139,000 after buying an additional 7,295 shares during the last quarter. Geode Capital Management LLC grew its stake in 908 Devices by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 581,300 shares of the company’s stock valued at $1,279,000 after buying an additional 13,512 shares during the last quarter. Northern Trust Corp grew its stake in 908 Devices by 7.5% in the 4th quarter. Northern Trust Corp now owns 200,764 shares of the company’s stock valued at $442,000 after buying an additional 14,087 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new position in 908 Devices in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

908 Devices Trading Up 3.9%

NASDAQ:MASS opened at $6.94 on Friday. 908 Devices Inc. has a 1 year low of $1.81 and a 1 year high of $7.32. The firm’s fifty day simple moving average is $5.03 and its 200 day simple moving average is $3.53. The firm has a market capitalization of $248.88 million, a PE ratio of -3.92 and a beta of 0.29.

908 Devices (NASDAQ:MASS) last posted its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. The business had revenue of $11.78 million for the quarter, compared to analyst estimates of $11.90 million. As a group, analysts anticipate that 908 Devices Inc. will post -1.99 EPS for the current fiscal year.

Insider Buying and Selling at 908 Devices

In other 908 Devices news, CFO Joseph H. Iv Griffith sold 6,940 shares of the stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $7.08, for a total value of $49,135.20. Following the completion of the sale, the chief financial officer now directly owns 102,930 shares of the company’s stock, valued at $728,744.40. This represents a 6.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark Spoto purchased 10,000 shares of 908 Devices stock in a transaction on Wednesday, May 14th. The stock was bought at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the acquisition, the director now owns 62,971 shares in the company, valued at approximately $270,145.59. This trade represents a 18.88% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 23.70% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 908 Devices in a research note on Saturday, May 24th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, 908 Devices presently has an average rating of “Moderate Buy” and a consensus price target of $5.33.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.